SecA Inhibitors Block Growth of Methicillin-Resistant Staphylococcus aureus
|
By LabMedica International staff writers Posted on 15 Dec 2015 |

Image: Colorized scanning electron micrograph (SEM) shows a grouping of methicillin resistant Staphylococcus aureus (MRSA) bacteria magnified 20,000 times (Photo courtesy of the CDC – US Centers for Disease Control and Prevention).
A novel class of low molecular weight compounds has been shown to effectively inhibit the growth of methicillin-resistant Staphylococcus aureus (MRSA), one of the most serious drug-resistant bacterial pathogens.
Investigators at Georgia State University (Atlanta, USA) had shown previously that small molecular components of the dye Rose Bengal (RB) were active against the bacteria Escherichia coli and Bacillus subtilis. This activity was found to be due to inhibition of SecA, a cell membrane-associated subunit of the eubacterial Sec or Type II secretory pathway, a system which is responsible for the secretion of proteins through the cell membrane. Within this system SecA has the functional properties of an ATPase and is required to empower the movement of the protein substrate across the translocation channel. Thus, SecA is a key component of the general bacterial secretion system required for viability and virulence.
In the current study, which was published in the November 1, 2015, issue of the journal Bioorganic & Medicinal Chemistry, the investigators evaluated two potent RB analogs for activities against MRSA strains and for their mechanism of actions.
These analogs inhibited the ATPase activities of S. aureus SecA1 (SaSecA1) and SecA2 (SaSecA2), and inhibited the SaSecA1-dependent protein-conducting channel. Moreover, these inhibitors reduced the secretion of three toxins from S. aureus and exerted potent bacteriostatic effects against three MRSA strains.
The best inhibitor, SCA-50, showed potent concentration-dependent bactericidal activity against MRSA Mu50 strain and very importantly, two to 60-fold more potent inhibitory effect on MRSA Mu50 than all the commonly used antibiotics including vancomycin, which is considered the last resort option in treating MRSA-related infections.
Deletion or overexpression of bacterial efflux pumps had minimal effect on the antimicrobial activities against S. aureus, indicating that the effects of SecA inhibitors were not affected by the presence of these efflux pumps. This study showed that these small molecule analogs of Rose Bengal targeted SecA functions, had potent antimicrobial activities, reduced the secretion of toxins, and had the ability to overcome the effect efflux pumps, which are responsible for multi-drug resistance.
"We have found that SecA inhibitors are broad-spectrum antimicrobials and are very effective against strains of bacteria that are resistant to existing antibiotics," said contributing author Dr. Binghe Wang, professor of chemistry at Georgia State University.
Related Links:
Georgia State University
Investigators at Georgia State University (Atlanta, USA) had shown previously that small molecular components of the dye Rose Bengal (RB) were active against the bacteria Escherichia coli and Bacillus subtilis. This activity was found to be due to inhibition of SecA, a cell membrane-associated subunit of the eubacterial Sec or Type II secretory pathway, a system which is responsible for the secretion of proteins through the cell membrane. Within this system SecA has the functional properties of an ATPase and is required to empower the movement of the protein substrate across the translocation channel. Thus, SecA is a key component of the general bacterial secretion system required for viability and virulence.
In the current study, which was published in the November 1, 2015, issue of the journal Bioorganic & Medicinal Chemistry, the investigators evaluated two potent RB analogs for activities against MRSA strains and for their mechanism of actions.
These analogs inhibited the ATPase activities of S. aureus SecA1 (SaSecA1) and SecA2 (SaSecA2), and inhibited the SaSecA1-dependent protein-conducting channel. Moreover, these inhibitors reduced the secretion of three toxins from S. aureus and exerted potent bacteriostatic effects against three MRSA strains.
The best inhibitor, SCA-50, showed potent concentration-dependent bactericidal activity against MRSA Mu50 strain and very importantly, two to 60-fold more potent inhibitory effect on MRSA Mu50 than all the commonly used antibiotics including vancomycin, which is considered the last resort option in treating MRSA-related infections.
Deletion or overexpression of bacterial efflux pumps had minimal effect on the antimicrobial activities against S. aureus, indicating that the effects of SecA inhibitors were not affected by the presence of these efflux pumps. This study showed that these small molecule analogs of Rose Bengal targeted SecA functions, had potent antimicrobial activities, reduced the secretion of toxins, and had the ability to overcome the effect efflux pumps, which are responsible for multi-drug resistance.
"We have found that SecA inhibitors are broad-spectrum antimicrobials and are very effective against strains of bacteria that are resistant to existing antibiotics," said contributing author Dr. Binghe Wang, professor of chemistry at Georgia State University.
Related Links:
Georgia State University
Latest BioResearch News
- D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
- New Genetic Cause Identified for Neurodevelopmental Disorder
- New Genetic Discovery Could Support Precision Diabetes Care
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
Channels
Clinical Chemistry
view channel
Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air
Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more
Head-to-Head Study Compares Blood Tests for Early Alzheimer’s Disease Detection
Accurate, scalable diagnostics are becoming increasingly important as disease-modifying therapies reshape Alzheimer’s disease care, yet many patients still rely on invasive cerebrospinal fluid sampling... Read more
Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy
Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read moreMolecular Diagnostics
view channel
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
Prenatal genetic testing is increasingly used to identify potential neurodevelopmental conditions, but results often include variants of uncertain significance that clinicians cannot confidently classify.... Read more
New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples
Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
Clinical decisions often rely on chronological age, yet organs can age biologically at different rates that remain hard to assess. Noninvasive detection of organ-specific aging could support disease monitoring... Read more
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more







